KNCV welcomes the new guidance issued by WHO on the treatment of drug resistant TB and applauds this important step towards safer, shorter, injection free regimens for MDR TB patients.
KNCV also supports that all patients have access to rapid molecular resistance testing: the right diagnosis for the right treatment.
For the last several years, KNCV , under the USAID funded Challenge TB project, has supported over a dozen countries to access rapid molecular testing and deploy new drugs and regimens, including bedaquiline; these countries now are in a good position to responsibly apply the new guidance with appropriate supportive systems.
Based on this experience, KNCV stands ready to assist any country during their transition.